Job Summary:
Palleon Pharmaceuticals is seeking a highly motivated, innovative, and collaborative Immunologist who has a deep understanding of inflammatory, autoimmune, and other immune-related indications to join our team. The candidate should be able to work independently with a demonstrated ability to advance drug discovery projects and/or biomarker strategy. This position will report to the Head of Translational Science and will partner with key stakeholders in discovery biology, protein engineering, and clinical development to discover and develop target hypotheses utilizing the industry-leading glyco-immunology platform developed at Palleon Pharmaceuticals.
Position Responsibilities:
- Address key translational research questions related to Palleon’s CONVERGENCE and EAGLE platforms, dissecting mechanisms of action and identifying novel biomarkers from peripheral blood and tissue samples
- Develop biomarker-related strategies for exploratory and clinical development
- Collaborate with internal research teams and external groups/CROs and/or other external academic/industry collaborators to implement biomarker-related strategies
- Design, develop and implement in vitro, in vivo, and ex vivo immunological models, flow cytometry-based assays, multiplex assays, and other techniques to support Palleon’s proprietary biologics, MOA characterization and PD studies, and to identify biomarkers
- Analyze immune data and present results to larger scientific groups, both internally and externally
- Provide guidance on and lead drafting of biomarker-related documents and sections within clinical and regulatory documents
- Work collaboratively in a team environment and independently to deliver against timelines
- Train and supervise research associates to achieve team and company goals
- Perform high level, quality data analysis, review in vivo study reports, and interpret study results to ensure high technical/scientific data integrity and document compliance with appropriate regulatory standards
- Keep up to date with the literature related to this area, and act as an expert resource for internal stakeholders who are driving translational strategy
Qualifications:
- Ph.D. in immunology, immune oncology, immune-related diseases, or related discipline with either 5+ years post-doctoral experience in academia or some industry experience; or Master’s Degree with 10+ years industry experience
- Extensive experience and knowledge, and deep understanding of T cells, myeloid biology including DCs, and macrophages
- Hands-on experience in the design, delivery, and management of various preclinical models of immune response, inflammatory diseases and/or anti-tumor immunity
- Hands-on experience in a wide range of ex vivo and in vitro experiments including primary cell cultures, tumor dissociation and processing, ELISA, flow cytometry, and various immune cell assays
- Proven track record in the fields of immunology and cancer biology as evidenced by publication record
- Commitment to working in a team-oriented environment, and willingness to contribute to shared project and organizational goals
- Ability to multi-task in a fast-paced drug discovery environment
- Demonstrated creativity, and ability to employ novel approaches to solving scientific problems
- Excellent interpersonal skills with the ability to interact effectively with people, internally and externally
- Excellent oral and written communication skills
- Industry experience desired but not required
Who We Are:
Palleon Pharmaceuticals, co-founded by Nobel laureate Carolyn Bertozzi, is a biotechnology company pioneering glyco-immunology drug development to transform the treatment of cancer and inflammatory diseases. The Company’s proprietary platforms overcome technical barriers unique to glycobiology to enable drug discovery, patient selection, and indication prioritization to de-risk clinical development. The company’s lead program in oncology, E-602, is a Phase 1/2, first-in-class, glyco-immune checkpoint inhibitor which restores antitumor immunity by enzymatically degrading immunosuppressive sialoglycans on hypersialylated tumors and immune cells. Palleon has a rich pipeline of additional drug candidates including several advancing toward IND-enabling studies.
